MARKET

MNMD

MNMD

Mind Medicine
NASDAQ
6.15
-0.31
-4.80%
After Hours: 6.33 +0.18 +2.93% 19:22 05/09 EDT
OPEN
6.46
PREV CLOSE
6.46
HIGH
6.53
LOW
6.03
VOLUME
946.72K
TURNOVER
--
52 WEEK HIGH
10.44
52 WEEK LOW
4.700
MARKET CAP
464.64M
P/E (TTM)
-6.5086
1D
5D
1M
3M
1Y
5Y
1D
MindMed’s Strategic Positioning and Financial Strength Underpin ‘Buy’ Rating
TipRanks · 15h ago
Mind Medicine Price Target Maintained With a $20.00/Share by Chardan Capital
Dow Jones · 22h ago
Mind Medicine Is Maintained at Buy by Chardan Capital
Dow Jones · 22h ago
Chardan Capital Maintains Buy on Mind Medicine, Maintains $20 Price Target
Benzinga · 22h ago
MindMed Advances Phase 3 Trials for Brain Health
TipRanks · 1d ago
Analysts Offer Insights on Healthcare Companies: Mind Medicine (MNMD) and AbCellera Biologics (ABCL)
TipRanks · 1d ago
Mind Medicine (MindMed) Inc reports results for the quarter ended March 31 - Earnings Summary
Reuters · 1d ago
Psychedelic: Compass, GH Research, MindMed report quarterly earnings
TipRanks · 1d ago
More
About MNMD
More
Mind Medicine (MindMed) Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. The Company is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, its lead product candidates. Its lead product candidate, MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that the Company is developing for the treatment of generalized anxiety disorder and major depressive disorder. Its second lead product candidate, MM402, also referred to as R(-)-MDMA, is its proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).
Recently
Symbol
Price
%Change

Webull offers Mind Medicine (MindMed) Inc stock information, including NASDAQ: MNMD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MNMD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MNMD stock methods without spending real money on the virtual paper trading platform.